{"id":6038,"date":"2024-06-03T07:21:52","date_gmt":"2024-06-03T05:21:52","guid":{"rendered":"https:\/\/alpha1-deutschland.org\/?p=6038"},"modified":"2024-06-03T11:39:04","modified_gmt":"2024-06-03T09:39:04","slug":"easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy","status":"publish","type":"post","link":"https:\/\/alpha1-deutschland.org\/en\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy","title":{"rendered":"EASL \u2013 Studio S6E6 \u2013 Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy"},"content":{"rendered":"

Am Tag der seltenen Krankheiten,\u00a0 29.02.2024,\u00a0 ver\u00f6ffentlicht EASL \u00a0European Association for the Study of the Liver<\/a> Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy<\/span><\/a><\/p>\n

Die G\u00e4ste Aftab Ala, unser Beirat von Alpha1 Deutschland Pavel Strnad und Alice Turner er\u00f6rtern die \u00fcberzeugenden Gr\u00fcnde, warum die AATD ein Hauptkandidat f\u00fcr die Gentherapie ist. Der Vortrag unter der Moderation von Aleksander Krag zeigt die Relevanz des Themas in der aktuellen Forschungslandschaft auf und weist auf laufende weltweite Studien hin, die neue M\u00f6glichkeiten auf diesem Gebiet er\u00f6ffnen<\/p>\n

\"\"<\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Am Tag der seltenen Krankheiten,\u00a0 29.02.2024,\u00a0 ver\u00f6ffentlicht EASL \u00a0European Association for the Study of the Liver Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy Die G\u00e4ste…<\/p>","protected":false},"author":6,"featured_media":6040,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,39],"tags":[],"class_list":["post-6038","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allgemein","category-alpha-1-leber"],"yoast_head":"\nEASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/alpha1-deutschland.org\/en\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte\" \/>\n<meta property=\"og:description\" content=\"Am Tag der seltenen Krankheiten,\u00a0 29.02.2024,\u00a0 ver\u00f6ffentlicht EASL \u00a0European Association for the Study of the Liver Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy Die G\u00e4ste...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/alpha1-deutschland.org\/en\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Ihr Online Portal f\u00fcr Mitglieder und Interessierte\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-03T05:21:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-03T09:39:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"948\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Thomas Heimann\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Thomas Heimann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\"},\"author\":{\"name\":\"Thomas Heimann\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/4cc3dc9d8aa967e68275fa7d2102b1ba\"},\"headline\":\"EASL – Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy\",\"datePublished\":\"2024-06-03T05:21:52+00:00\",\"dateModified\":\"2024-06-03T09:39:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\"},\"wordCount\":112,\"image\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/EASL-Studio-Banner-1.png\",\"articleSection\":[\"Allgemein\",\"Alpha-1 & Leber\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\",\"name\":\"EASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/EASL-Studio-Banner-1.png\",\"datePublished\":\"2024-06-03T05:21:52+00:00\",\"dateModified\":\"2024-06-03T09:39:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/4cc3dc9d8aa967e68275fa7d2102b1ba\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/EASL-Studio-Banner-1.png\",\"contentUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/EASL-Studio-Banner-1.png\",\"width\":948,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/alpha1-deutschland.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EASL – Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#website\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/\",\"name\":\"Ihr Online Portal f\u00fcr Mitglieder und Interessierte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/alpha1-deutschland.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/4cc3dc9d8aa967e68275fa7d2102b1ba\",\"name\":\"Thomas Heimann\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/en\\\/author\\\/heimann\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/alpha1-deutschland.org\/en\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\/","og_locale":"en_GB","og_type":"article","og_title":"EASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte","og_description":"Am Tag der seltenen Krankheiten,\u00a0 29.02.2024,\u00a0 ver\u00f6ffentlicht EASL \u00a0European Association for the Study of the Liver Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy Die G\u00e4ste...","og_url":"https:\/\/alpha1-deutschland.org\/en\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy\/","og_site_name":"Ihr Online Portal f\u00fcr Mitglieder und Interessierte","article_published_time":"2024-06-03T05:21:52+00:00","article_modified_time":"2024-06-03T09:39:04+00:00","og_image":[{"width":948,"height":200,"url":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png","type":"image\/png"}],"author":"Thomas Heimann","twitter_misc":{"Written by":"Thomas Heimann","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#article","isPartOf":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy"},"author":{"name":"Thomas Heimann","@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/4cc3dc9d8aa967e68275fa7d2102b1ba"},"headline":"EASL – Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy","datePublished":"2024-06-03T05:21:52+00:00","dateModified":"2024-06-03T09:39:04+00:00","mainEntityOfPage":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy"},"wordCount":112,"image":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage"},"thumbnailUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png","articleSection":["Allgemein","Alpha-1 & Leber"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy","url":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy","name":"EASL - Studio S6E6 - Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy - Ihr Online Portal f\u00fcr Mitglieder und Interessierte","isPartOf":{"@id":"https:\/\/alpha1-deutschland.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage"},"image":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage"},"thumbnailUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png","datePublished":"2024-06-03T05:21:52+00:00","dateModified":"2024-06-03T09:39:04+00:00","author":{"@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/4cc3dc9d8aa967e68275fa7d2102b1ba"},"breadcrumb":{"@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#primaryimage","url":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png","contentUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/EASL-Studio-Banner-1.png","width":948,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/alpha1-deutschland.org\/easl-studio-s6e6-alpha-1-antitrypsin-deficiency-aatd-a-poster-child-for-genetic-therapy#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/alpha1-deutschland.org\/"},{"@type":"ListItem","position":2,"name":"EASL – Studio S6E6 – Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy"}]},{"@type":"WebSite","@id":"https:\/\/alpha1-deutschland.org\/#website","url":"https:\/\/alpha1-deutschland.org\/","name":"Your online portal for members and interested parties","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/alpha1-deutschland.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/4cc3dc9d8aa967e68275fa7d2102b1ba","name":"Thomas Heimann","url":"https:\/\/alpha1-deutschland.org\/en\/author\/heimann"}]}},"_links":{"self":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts\/6038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/comments?post=6038"}],"version-history":[{"count":0,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts\/6038\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/media\/6040"}],"wp:attachment":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/media?parent=6038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/categories?post=6038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/tags?post=6038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}